We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+22.97%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$5.81B
AUM Growth
-$1.23B
Cap. Flow
-$2B
Cap. Flow %
-34.5%
Top 10 Hldgs %
69.35%
Holding
53
New
7
Increased
14
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$374M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$100M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$96.8M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$81.7M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$60.1M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$2.23B
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$257M
3
KPTI icon
Karyopharm Therapeutics
KPTI
+$87.6M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$80.8M
5
QURE icon
uniQure
QURE
+$64.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$996M 17.15%
4,535,000
+192,000
+4% +$41.5M
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$658M 11.34%
9,000,000
+1,350,000
+18% +$100M
UTHR icon
3
United Therapeutics
UTHR
$26B
$433M 7.45%
+2,850,000
New +$374M
IOVA icon
4
Iovance Biotherapeutics
IOVA
$2.07B
$348M 5.99%
7,500,000
-2,036,039
-21% -$80.8M
ARNA
5
DELISTED
Arena Pharmaceuticals Inc
ARNA
$322M 5.54%
4,190,000
+1,090,000
+35% +$81.7M
ASND icon
6
Ascendis Pharma A/S
ASND
$16.7B
$300M 5.17%
1,800,000
– –
SRPT icon
7
Sarepta Therapeutics
SRPT
$1.66B
$298M 5.14%
1,750,000
+75,000
+4% +$11.1M
ARGX icon
8
argenx
ARGX
$55.1B
$265M 4.57%
902,500
– –
FOLD
9
DELISTED
Amicus Therapeutics
FOLD
$208M 3.58%
9,000,000
-1,850,000
-17% -$37.8M
XLRN
10
DELISTED
Acceleron Pharma
XLRN
$198M 3.42%
1,550,000
+200,000
+15% +$23.5M
MRSN
11
DELISTED
Mersana Therapeutics
MRSN
$181M 3.12%
272,000
– –
BMRN icon
12
BioMarin Pharmaceuticals
BMRN
$11.9B
$145M 2.49%
1,650,000
-100,000
-6% -$7.93M
MDGL icon
13
Madrigal Pharmaceuticals
MDGL
$12.5B
$136M 2.35%
1,225,000
+335,000
+38% +$40.9M
KURA icon
14
Kura Oncology
KURA
$815M
$131M 2.25%
4,000,000
+1,565,000
+64% +$55M
PMVP icon
15
PMV Pharmaceuticals
PMVP
$57.1M
$131M 2.25%
2,350,267
+500,267
+27% +$19.6M
ACAD icon
16
Acadia Pharmaceuticals
ACAD
$4.52B
$104M 1.8%
+1,950,000
New +$96.8M
ADVM
17
DELISTED
Adverum Biotechnologies
ADVM
$86.7M 1.49%
800,000
– –
TRIL
18
DELISTED
Trillium Therapeutics Inc.
TRIL
$85.3M 1.47%
5,800,000
+300,000
+5% +$4.33M
CNST
19
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$85M 1.46%
2,950,000
-1,325,000
-31% -$33.4M
DCPH
20
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$74.2M 1.28%
1,300,000
-520,000
-29% -$30.8M
PRAX icon
21
Praxis Precision Medicines
PRAX
$8.21B
$68.7M 1.18%
+103,033
New +$60.1M
CBAY
22
DELISTED
Cymabay Therapeutics
CBAY
$59.1M 1.02%
10,300,000
– –
ISEE
23
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$50.1M 0.86%
7,250,000
– –
TVTX icon
24
Travere Therapeutics
TVTX
$5.24B
$49.1M 0.85%
1,800,500
+475,500
+36% +$11.1M
RLMD icon
25
Relmada Therapeutics
RLMD
$546M
$48.9M 0.84%
1,525,000
+25,000
+2% +$859K
1
2 3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q4 2020 Portfolio in Review

As of Q4 2020, Avoro Capital Advisors held 53 positions worth $5.81B, down 18% from $7.04B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Avoro Capital Advisors withdrew a net $2B in Q4 2020, closing 9 positions and reducing 8 holdings. Its most notable exit was Immunomedics Inc, an estimated $2.23B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 67% a quarter earlier.

Against the trend, Avoro Capital Advisors opened a new position in United Therapeutics worth $433M.

  • Avoro Capital Advisors's largest Q4 2020 buy was United Therapeutics: 2,850,000 shares worth $433M.
  • Avoro Capital Advisors added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020, an estimated $100M increase.
  • Avoro Capital Advisors's biggest Q4 2020 reduction was Iovance Biotherapeutics, cutting an estimated $80.8M.
  • Avoro Capital Advisors fully exited Immunomedics Inc in Q4 2020, selling an estimated $2.23B.
  • Avoro Capital Advisors's ten largest holdings make up 69% of its $5.81B portfolio in Q4 2020.
  • Avoro Capital Advisors opened 7 new positions and closed 9 in Q4 2020.
  • Avoro Capital Advisors's portfolio value fell 18% quarter-over-quarter to $5.81B.

Based on Avoro Capital Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.